🟢 $PRQR Target 7.45 for 19.39% Or double position at 5.03 — On the far right of the chart is my Average (Grey) Current Target (Green), and Next Level to add (Red) Percentage to target is from my average. I start every position with 1% of my account and build from there as needed and as possible. I am not your financial advisor. Watch my setups first...
LOW; $18. MID: $26. HIGHL $44(!!).
Hi everyone, there is a possible buy opportunity with PROQR. Probably the price will consolided for a while in the 5.50/6 area, or even get a bit lower, but then it should turn to the upside and aim for the a new highs. Cheers
Bullish Pennant (63%) Pros: Volume during post formation Descending volume during triangle formation Golden cross in blue PPS above 50MA and 200MA RS above 0 and ascending R/R ratio above 7 ATR ascending 250RSI above 50 and ascending Cons: 200MA Flat/descending Target: PT = 13.49$ Help how ever you can to keep this alive. Thank you to those who have donated...
ProQR Announces Positive Results from Clinical Trial of QR-421a in Usher Syndrome and Plans to Start Pivotal Trials. QR-421a demonstrated a concordant benefit in multiple measures of vision, including best corrected visual activity (BCVA), static perimetry, and retinal imaging (OCT) QR-421a observed to be well tolerated with no serious adverse events...
Potential gain:90-120% Reward/Risk:6-9 Timeframe: 3-9 months I always try to present the charts in a simple comprehensive format to prevent any confusion. This is just my technical view, neither a fundamental comment,nor a recommendation to trade..! Please review my track record and calculate the odds for yourself..! You’re likes and comments encourage me to...
Might be a chance of some nice profits today with PRQR. Though its in a long bearish trend this short bullish swing could me some profits for the day. There has been stead increase in activity since November and it only broke into the oversold area of the RSI recently, we think this should counter with a comparable move into the overbought area. STOP LOSS around...
This one is just flat out sexy. Just a matter if it can break trend soon or can't and sells down further. Either way this is a ticking time bomb and must be on your watchlist.
Results from the interim analysis: Efficacy data: Approximately 60% of subjects showed a clinically meaningful response in visual acuity and mobility course endpoints at three months of treatment and there was general concordance across the endpoints. Visual acuity: In the majority of patients, there was a substantive overall improvement in best corrected visual...
PRQR: ProQR Therapeutics N.V. 2018-09-05 04:00:00 ProQR Announces Positive Interim Results from Phase 1/2 Clinical Trial of QR-110 in LCA10 Patients, and Plans to Start a Phase 2/3 Pivotal Trial
Another biotech .. at alomost zero E/V ... www.tradingsignalreviews.com